Supernus Pharms patents expiration
1. Oxtellar Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617600 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9855278 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US11166960 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US8821930 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US7722898 | SUPERNUS PHARMS | Modified-release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9351975 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9370525 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US7910131 | SUPERNUS PHARMS | Method of treating seizures using modified release formulations of oxcarbazepine |
Apr, 2027
(2 years from now) | |
| US9119791 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US10220042 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 19, 2015 |
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 19 October, 2012
Treatment: Treatment of partial-onset seizures
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXTELLAR XR family patents
2. Qelbree patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
| US11458143 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
| New Patient Population(NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QELBREE family patents
3. Trokendi Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8298580 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8992989 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8663683 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8889191 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US10314790 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US9549940 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8877248 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US9555004 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US9622983 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Nov, 2027
(3 years from now) | |
| US8298576 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Apr, 2028
(3 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 16 August, 2013
Treatment: Treatment of epilepsy; Use of trokendi xr for the treatment of epilepsy; Use of trokendi xr for prophylactic treatment of migraine
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
TROKENDI XR family patents